- British Business Bank is set to invest up to €53.6 million (£46 million) in Zinc's new Science-for-Impact Fund.
- The Science-for-Impact Fund aims to raise a total of €81.5 million (£70 million) and will support 80 deep tech startups emerging from UK research in health and climate.
- This investment marks the British Business Bank's second major commitment to Zinc, following its support for Zinc's earlier fund in 2022.
- Founded in 2017, Zinc is a pre-Seed venture capital firm that backs ambitious founders building Science-for-Impact companies in health and the environment.
- The Enterprise Capital Funds programme aims to increase the supply of equity capital to early-stage UK companies with long-term growth potential.
- Zinc's strategy involves collaborating with researchers before any business plans are drawn up, focusing on building companies around scientific breakthroughs.
The British Business Bank has committed up to €53.6 million (£46 million) to Zinc's Science-for-Impact Fund, which targets a total fund size of €81.5 million (£70 million). This initiative aims to support 80 deep tech startups focused on health and climate solutions emerging from UK research.12
Zinc's strategy involves engaging scientists early in the process, allowing for the development of companies that align with government priorities in advanced manufacturing, clean energy, life sciences, engineering, biology, and AI. The fund is part of the Bank's Enterprise Capital Funds programme, which has supported 55 funds since its inception.5

Mark Sims, Managing Director at the British Business Bank, stated, “Breakthrough businesses need support from the very earliest stages if they’re to realise their potential. Zinc has a strong track record of backing founders tackling significant health and environmental challenges.” Zinc co-founder emphasized the fund's role in addressing the gap between UK research output and commercialized businesses, stating, “Too many breakthrough discoveries never become the companies that improve lives.”
Zinc's portfolio includes innovative companies like Epiome, an AI biomarker platform for neurodegenerative diseases, and CellMine, which focuses on recycling lithium-ion batteries. The fund aims to de-risk scientific innovation and accelerate the commercial progress of these startups, ultimately contributing to the UK's future economy.
“The fund is the 55th within the Enterprise Capital Funds programme, which aims to increase equity capital for early-stage UK companies. Zinc's portfolio includes Epiome, an AI biomarker platform for Alzheimer's and Parkinson's, and CellMine, a lithium-ion battery recycling process.”






